TRAIL-mediated killing of acute lymphoblastic leukemia by plasmacytoid dendritic cell-activated natural killer cells

Oncotarget

Volumn 6, Issue 30, 2015, Pages 29440-29455

  Lelaidier, Martin ^a,b   Dìaz Rodriguez, Yildian ^a,b   Cordeau, Martine ^a,b   Cordeiro, Paulo ^a   Haddad, Elie ^a,b   Herblot, Sabine ^a,b   Duval, Michel ^a,b  

^a UNIVERSITY OF MONTREAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Interferon alpha; Natural killer cells; Pediatric acute lymphoblastic leukemia; Plasmacytoid dendritic cells; TRAIL

Indexed keywords

ALPHA INTERFERON; CD69 ANTIGEN; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; GAMMA INTERFERON; IFNG PROTEIN, HUMAN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; LECTIN; LEUKOCYTE ANTIGEN; T LYMPHOCYTE ANTIGEN; TLR9 PROTEIN, HUMAN; TNFSF10 PROTEIN, HUMAN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DETECTION; APOPTOSIS; ARTICLE; CANCER RECURRENCE; CANCER RESISTANCE; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOLYSIS; DEGRANULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNOPHENOTYPING; MEMBRANE PERMEABILITY; MOUSE; NATURAL KILLER CELL; NEWBORN; NONHUMAN; NORMAL HUMAN; PHENOTYPE; PLASMACYTOID DENDRITIC CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UPREGULATION; ADOPTIVE IMMUNOTHERAPY; ANIMAL; CELL DEATH; COCULTURE; CYTOTOXICITY; DENDRITIC CELL; DRUG SCREENING; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SCID MOUSE; SIGNAL TRANSDUCTION; TIME FACTOR; TRANSPLANTATION; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CELL DEATH; CELL DEGRANULATION; CELL LINE, TUMOR; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-ALPHA; INTERFERON-GAMMA; KILLER CELLS, NATURAL; LECTINS, C-TYPE; LYMPHOCYTE ACTIVATION; MICE, INBRED NOD; MICE, SCID; PHENOTYPE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECEPTORS, KIR; SIGNAL TRANSDUCTION; TIME FACTORS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TOLL-LIKE RECEPTOR 9; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84945138235     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4984     Document Type: Article

References (58)

1. Hunger SP, Lu X, Devidas M, Camitta BM, Gaynon PS, Winick NJ, Reaman GH and Carroll WL. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2012; 30:1663-1669.
2. Pui CH, Gaynon PS, Boyett JM, Chessells JM, Baruchel A, Kamps W, Silverman LB, Biondi A, Harms DO, Vilmer E, Schrappe M and Camitta B. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet. 2002; 359:1909-1915.
3. Behm FG, Raimondi SC, Frestedt JL, Liu Q, Crist WM, Downing JR, Rivera GK, Kersey JH and Pui CH. Rearrangement of the MLL gene confers a poor prognosis in childhood acute lymphoblastic leukemia, regardless of presenting age. Blood. 1996; 87:2870-2877.
4. Charrier E, Cordeiro P, Brito RM, Mezziani S, Herblot S, Le Deist F and Duval M. Reconstitution of maturating and regulatory lymphocyte subsets after cord blood and BMT in children. Bone marrow transplantation. 2013; 48:376-382.
5. Renard C, Barlogis V, Mialou V, Galambrun C, Bernoux D, Goutagny MP, Glasman L, Loundou AD, Poitevin-Later F, Dignat-George F, Dubois V, Picard C, Chabannon C, Bertrand Y and Michel G. Lymphocyte subset reconstitution after unrelated cord blood or bone marrow transplantation in children. British journal of haematology. 2011; 152:322-330.
6. Foley B, Felices M, Cichocki F, Cooley S, Verneris MR and Miller JS. The biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (HCT). Immunological reviews. 2014; 258:45-63.
7. Moretta A, Bottino C, Mingari MC, Biassoni R and Moretta L. What is a natural killer cell? Nature immunology. 2002; 3:6-8.
8. Hilpert J, Grosse-Hovest L, Grunebach F, Buechele C, Nuebling T, Raum T, Steinle A and Salih HR. Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses. Journal of immunology. 2012; 189:1360-1371.
9. Bakker AB, Wu J, Phillips JH and Lanier LL. NK cell activation: distinct stimulatory pathways counterbalancing inhibitory signals. Human immunology. 2000; 61:18-27.
10. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, Biassoni R and Moretta L. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annual review of immunology. 2001; 19:197-223.
11. Vivier E and Ugolini S. Natural killer cells: from basic research to treatments. Frontiers in Immunology. 2011; 2:1-4.
12. Moretta A, Bottino C, Vitale M, Pende D, Biassoni R, Mingari MC and Moretta L. Receptors for HLA class-I molecules in human natural killer cells. Annual review of immunology. 1996; 14:619-648.
13. Lowin B, Peitsch MC and Tschopp J. Perforin and granzymes: crucial effector molecules in cytolytic T lymphocyte and natural killer cell-mediated cytotoxicity. Current topics in microbiology and immunology. 1995; 198:1-24.
14. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J and Dixit VM. The receptor for the cytotoxic ligand TRAIL. Science. 1997; 276:111-113.
15. Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, Timour MS, Gerhart MJ, Schooley KA, Smith CA, Goodwin RG and Rauch CT. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. The EMBO journal. 1997; 16:5386-5397.
16. Geijtenbeek TB, van Kooyk Y, van Vliet SJ, Renes MH, Raymakers RA and Figdor CG. High frequency of adhesion defects in B-lineage acute lymphoblastic leukemia. Blood. 1999; 94:754-764.
17. Pende D, Spaggiari GM, Marcenaro S, Martini S, Rivera P, Capobianco A, Falco M, Lanino E, Pierri I, Zambello R, Bacigalupo A, Mingari MC, Moretta A and Moretta L. Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112). Blood. 2005; 105:2066-2073.
18. Romanski A, Bug G, Becker S, Kampfmann M, Seifried E, Hoelzer D, Ottmann OG and Tonn T. Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia. Experimental hematology. 2005; 33:344-352.
19. Ferlazzo G, Tsang ML, Moretta L, Melioli G, Steinman RM and Munz C. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. The Journal of experimental medicine. 2002; 195:343-351.
20. Zhang H, Cui Y, Voong N, Sabatino M, Stroncek DF, Morisot S, Civin CI, Wayne AS, Levine BL and Mackall CL. Activating signals dominate inhibitory signals in CD137L/IL-15 activated natural killer cells. Journal of immunotherapy. 2011; 34:187-195.
21. Colonna M, Trinchieri G and Liu YJ. Plasmacytoid dendritic cells in immunity. Nature immunology. 2004; 5:1219-1226.
22. Gerosa F, Gobbi A, Zorzi P, Burg S, Briere F, Carra G and Trinchieri G. The reciprocal interaction of NK cells with plasmacytoid or myeloid dendritic cells profoundly affects innate resistance functions. Journal of immunology. 2005; 174:727-734.
23. Piccioli D, Sbrana S, Melandri E and Valiante NM. Contactdependent stimulation and inhibition of dendritic cells by natural killer cells. The Journal of experimental medicine. 2002; 195:335-341.
24. Lou Y, Liu C, Kim GJ, Liu YJ, Hwu P and Wang G. Plasmacytoid dendritic cells synergize with myeloid dendritic cells in the induction of antigen-specific antitumor immune responses. Journal of immunology. 2007; 178:1534-1541.
25. Dalod M, Hamilton T, Salomon R, Salazar-Mather TP, Henry SC, Hamilton JD and Biron CA. Dendritic cell responses to early murine cytomegalovirus infection: subset functional specialization and differential regulation by interferon alpha/beta. The Journal of experimental medicine. 2003; 197:885-898.
26. Charrier E, Cordeiro P, Brito RM, Harnois M, Mezziani S, Herblot S, Le Deist F and Duval M. Impaired interferonalpha production by plasmacytoid dendritic cells after cord blood transplantation in children: implication for post-transplantation toll-like receptor ligandbased immunotherapy. Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation. 2014; 20:1501-1507.
27. Fitzgerald-Bocarsly P and Feng D. The role of type I interferon production by dendritic cells in host defense. Biochimie. 2007; 89:843-855.
28. Alter G, Malenfant JM and Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. Journal of immunological methods. 2004; 294(1-2):15-22.
29. Torelli GF, Peragine N, Raponi S, Pagliara D, De Propris MS, Vitale A, Bertaina A, Barberi W, Moretta L, Basso G, Santoni A, Guarini A, Locatelli F and Foa R. Recognition of adult and pediatric acute lymphoblastic leukemia blasts by natural killer cells. Haematologica. 2014; 99:1248-1254.
30. Thordardottir S, Hangalapura BN, Hutten T, Cossu M, Spanholtz J, Schaap N, Radstake TR, van der Voort R and Dolstra H. The aryl hydrocarbon receptor antagonist StemRegenin 1 promotes human plasmacytoid and myeloid dendritic cell development from CD34+ hematopoietic progenitor cells. Stem cells and development. 2014; 23:955-967.
31. van Beek JJ, Wimmers F, Hato SV, de Vries IJ and Skold AE. Dendritic Cell Cross Talk with Innate and Innate-like Effector Cells in Antitumor Immunity: Implications for DC Vaccination. Critical reviews in immunology. 2014; 34:517-536.
32. Walzer T, Dalod M, Robbins SH, Zitvogel L and Vivier E. Natural-killer cells and dendritic cells: "l'union fait la force". Blood. 2005; 106:2252-2258.
33. Swann JB, Hayakawa Y, Zerafa N, Sheehan KC, Scott B, Schreiber RD, Hertzog P and Smyth MJ. Type I IFN contributes to NK cell homeostasis, activation, and antitumor function. Journal of immunology. 2007; 178:7540-7549.
34. Benlahrech A, Donaghy H, Rozis G, Goodier M, Klavinskis L, Gotch F and Patterson S. Human NK Cell Up-regulation of CD69, HLA-DR, Interferon gamma Secretion and Cytotoxic Activity by Plasmacytoid Dendritic Cells is Regulated through Overlapping but Different Pathways. Sensors. 2009; 9:386-403.
35. Romagnani C, Della Chiesa M, Kohler S, Moewes B, Radbruch A, Moretta L, Moretta A and Thiel A. Activation of human NK cells by plasmacytoid dendritic cells and its modulation by CD4+ T helper cells and CD4+ CD25hi T regulatory cells. European journal of immunology. 2005; 35:2452-2458.
36. Akahane K, Inukai T, Zhang X, Hirose K, Kuroda I, Goi K, Honna H, Kagami K, Nakazawa S, Endo K, Kubota T, Yagita H, Koyama-Okazaki T and Sugita K. Resistance of T-cell acute lymphoblastic leukemia to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis. Experimental hematology. 2010; 38:885-895.
37. Castro Alves C, Terziyska N, Grunert M, Gundisch S, Graubner U, Quintanilla-Martinez L and Jeremias I. Leukemia-initiating cells of patient-derived acute lymphoblastic leukemia xenografts are sensitive toward TRAIL. Blood. 2012; 119:4224-4227.
38. Bryceson YT, Ljunggren HG and Long EO. Minimal requirement for induction of natural cytotoxicity and intersection of activation signals by inhibitory receptors. Blood. 2009; 114:2657-2666.
39. Wang H and Yang YG. The complex and central role of interferon-gamma in graft-versus-host disease and graftversus-tumor activity. Immunological reviews. 2014; 258:30-44.
40. Cao W. Molecular characterization of human plasmacytoid dendritic cells. Journal of clinical immunology. 2009; 29:257-264.
41. Chen W, Antonenko S, Sederstrom JM, Liang X, Chan AS, Kanzler H, Blom B, Blazar BR and Liu YJ. Thrombopoietin cooperates with FLT3-ligand in the generation of plasmacytoid dendritic cell precursors from human hematopoietic progenitors. Blood. 2004; 103:2547-2553.
42. Fujii H, Trudeau JD, Teachey DT, Fish JD, Grupp SA, Schultz KR and Reid GS. In vivo control of acute lymphoblastic leukemia by immunostimulatory CpG oligonucleotides. Blood. 2007; 109:2008-2013.
43. Seif AE, Barrett DM, Milone M, Brown VI, Grupp SA and Reid GS. Long-term protection from syngeneic acute lymphoblastic leukemia by CpG ODN-mediated stimulation of innate and adaptive immune responses. Blood. 2009; 114:2459-2466.
44. Horvath R, Budinsky V, Kayserova J, Kalina T, Formankova R, Stary J, Bartunkova J, Sedlacek P and Spisek R. Kinetics of dendritic cells reconstitution and costimulatory molecules expression after myeloablative allogeneic haematopoetic stem cell transplantation: implications for the development of acute graft-versus host disease. Clinical immunology. 2009; 131:60-69.
45. Fagnoni FF, Oliviero B, Giorgiani G, De Stefano P, Deho A, Zibera C, Gibelli N, Maccario R, Da Prada G, Zecca M and Locatelli F. Reconstitution dynamics of plasmacytoid and myeloid dendritic cell precursors after allogeneic myeloablative hematopoietic stem cell transplantation. Blood. 2004; 104:281-289.
46. Bluestone JA. The yin and yang of interleukin-2-mediated immunotherapy. N Engl J Med. 2011; 365:2129-2131.
47. Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea EP, 3rd, Armand P, Cutler C, Ho VT, Treister NS, Bienfang DC, Prasad S, Tzachanis D, Joyce RM, Avigan DE, Antin JH, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011; 365:2055-2066.
48. Van den Bergh JM, Van Tendeloo VF and Smits EL. Interleukin-15: New kid on the block for antitumor combination therapy. Cytokine & growth factor reviews. 2014.
49. Williams MT, Yousafzai Y, Cox C, Blair A, Carmody R, Sai S, Chapman KE, McAndrew R, Thomas A, Spence A, Gibson B, Graham GJ and Halsey C. Interleukin-15 enhances cellular proliferation and upregulates CNS homing molecules in pre-B acute lymphoblastic leukemia. Blood. 2014; 123:3116-3127.
50. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF and Velardi A. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002; 295:2097-2100.
51. Ruggeri L, Mancusi A, Burchielli E, Capanni M, Carotti A, Aloisi T, Aversa F, Martelli MF and Velardi A. NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation. Blood cells, molecules & diseases. 2008; 40:84-90.
52. Willemze R, Rodrigues CA, Labopin M, Sanz G, Michel G, Socie G, Rio B, Sirvent A, Renaud M, Madero L, Mohty M, Ferra C, Garnier F, Loiseau P, Garcia J, Lecchi L, et al. KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. Leukemia. 2009; 23:492-500.
53. Feuchtinger T, Pfeiffer M, Pfaffle A, Teltschik HM, Wernet D, Schumm M, Lotfi R, Handgretinger R and Lang P. Cytolytic activity of NK cell clones against acute childhood precursor-B-cell leukaemia is influenced by HLA class I expression on blasts and the differential KIR phenotype of NK clones. Bone marrow transplantation. 2009; 43:875-881.
54. Leung W, Iyengar R, Turner V, Lang P, Bader P, Conn P, Niethammer D and Handgretinger R. Determinants of antileukemia effects of allogeneic NK cells. Journal of immunology. 2004; 172:644-650.
55. Kubler A, Woiterski J, Witte KE, Buhring HJ, Hartwig UF, Ebinger M, Oevermann L, Mezger M, Herr W, Lang P, Handgretinger R, Munz C and Andre MC. Both mature KIR+ and immature KIR-NK cells control pediatric acute B cell precursor leukemia in NOD.Cg-Prkdcscid IL2rgtmWjl/Sz mice. Blood. 2014.
56. El-Sherbiny YM, Meade JL, Holmes TD, McGonagle D, Mackie SL, Morgan AW, Cook G, Feyler S, Richards SJ, Davies FE, Morgan GJ and Cook GP. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cellmediated killing of myeloma cells. Cancer research. 2007; 67:8444-8449.
57. Huntington ND, Legrand N, Alves NL, Jaron B, Weijer K, Plet A, Corcuff E, Mortier E, Jacques Y, Spits H and Di Santo JP. IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. The Journal of experimental medicine. 2009; 206:25-34.
58. Xu W, Jones M, Liu B, Zhu X, Johnson CB, Edwards AC, Kong L, Jeng EK, Han K, Marcus WD, Rubinstein MP, Rhode PR and Wong HC. Efficacy and mechanism-ofaction of a novel superagonist interleukin-15: interleukin-15 receptor alphaSu/Fc fusion complex in syngeneic murine models of multiple myeloma. Cancer research. 2013; 73:3075-3086.